Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Integral Investment Advisors Inc.

Integral Investment Advisors Inc. grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,581 shares of the medical research company’s stock after purchasing an additional 997 shares during the quarter. Integral Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $1,782,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of TMO. Handelsbanken Fonder AB raised its holdings in shares of Thermo Fisher Scientific by 5.2% during the first quarter. Handelsbanken Fonder AB now owns 393,531 shares of the medical research company’s stock worth $195,821,000 after purchasing an additional 19,311 shares during the period. Petredis Investment Advisors LLC grew its position in shares of Thermo Fisher Scientific by 1.0% during the 1st quarter. Petredis Investment Advisors LLC now owns 7,199 shares of the medical research company’s stock valued at $3,582,000 after buying an additional 72 shares during the last quarter. Ameliora Wealth Management Ltd. lifted its holdings in Thermo Fisher Scientific by 6.5% in the first quarter. Ameliora Wealth Management Ltd. now owns 558 shares of the medical research company’s stock worth $278,000 after acquiring an additional 34 shares during the last quarter. Simplicity Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 26.7% during the first quarter. Simplicity Wealth LLC now owns 1,452 shares of the medical research company’s stock valued at $723,000 after purchasing an additional 306 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after purchasing an additional 877 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 1.7%

NYSE:TMO opened at $408.57 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88. The firm has a market capitalization of $154.23 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 2.99 and a beta of 0.78. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The business’s fifty day moving average price is $419.12 and its 200 day moving average price is $494.94.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.11 earnings per share. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on TMO shares. Royal Bank of Canada dropped their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. UBS Group dropped their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a report on Thursday, April 24th. Finally, Robert W. Baird cut their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $605.30.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.